Gyre Therapeutics, Inc. (GYRE) Others — Quarterly & Annual

Screener

Others at other companies

Taboola.com Ltd.TBLA

$10.21M-58.3%

KlaviyoKVYO

$122.6M-14.3%

Power IntegrationsPOWI

$5.44M—

SiTime CorporationSITM

$1.93M—

Beyond MeatBYND

$42.5M-18.7%

Gyre Therapeutics, Inc.GYRE

$302K—

Other financials

Income statement

Revenue$29.1M-2.1%

Gross profit$26.9M-5.9%

Operating income-$14.4M-541%

Net income-$11.7M-471%

EPS (diluted)-$0.12-300%

Balance sheet

Cash & equivalents$43.3M+18.6%

Total debt$3.4M+145%

Total equity$107.9M+17.3%

Total assets$199.3M+30.5%

Cash flow

Operating cash flow-$16.7M-124%

CapEx$262.0K-21.8%

Free cash flow-$17.0M-118%

Valuation

Market cap$712.55M+11.2%

Enterprise value$672.68M+11.0%

P/S6×-0.1×

Profitability

Gross margin94.3%-1.7pp

Operating margin-14%-18.7pp

Net margin-13.4%-15.1pp

FCF margin-5.1%—

Returns & leverage

Return on equity-16%-18.3pp

Debt / equity0×0.0×

Current ratio4.3×-1.1×

Where this comes from

Reported directly by Gyre Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:PrepaidExpenseNoncurrent.

The source filing: Gyre Therapeutics, Inc.’s 10-Q, filed August 7, 2026. Open the filing →

Filed: Aug 7, 2026, 5:00 PM EDT
Fiscal quarter: Q2 FY2026
Calendar quarter: Q2 2026
Accession: 0001193125-26-340448

FAQ

What is Gyre Therapeutics, Inc.'s others?: Gyre Therapeutics, Inc. (GYRE) reported others of $302K in Q2 2026.
What does others mean?: Others as reported by Gyre Therapeutics, Inc. Common Stock.

Ask your AI about Gyre Therapeutics, Inc.'s others.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk